Itulazax (Betula Verrucosa (108))

Betula verrucosa, the active ingredient in Itulazax, is an allergen extract presented as a sublingual formulation for sublingual use. It is employed to treat allergic rhinitis caused by birch (Betula verrucosa) pollen in sensitized individuals, administered under medical supervision to induce tolerance.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for allergen immunotherapy products. The company adheres to Good Distribution Practice, provides temperature‑controlled shipping where required, and supports regulatory documentation for importers.

Itulazax is used in allergy immunotherapy to address birch pollen‑induced allergic rhinitis.

Allergic rhinitis due to Betula verrucosa pollen: reduces nasal congestion, sneezing and itching. Seasonal allergic rhinoconjunctivitis caused by birch pollen: improves overall symptom control. Birch pollen‑induced allergic conjunctivitis: alleviates eye irritation and redness.

Common Side Effects: - Oral itching or mild irritation - Throat discomfort or mild swelling of the lips - Transient nasal irritation or sneezing - Mild headache - Temporary gastrointestinal discomfort - Mild urticaria at the site of administration

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction - Angioedema affecting face or airway - Severe bronchospasm or respiratory distress - Generalized urticaria or hives - Eosinophilic esophagitis - Cardiovascular collapse in extreme cases

Before initiating therapy, clinicians should evaluate patient suitability and monitor for reactions.

Assess patient allergy history: confirm documented sensitivity to Betula verrucosa before starting. Monitor for local reactions: observe for oral itching or swelling after the first dose. Avoid use in uncontrolled asthma: risk of bronchospasm may be heightened. Do not combine with other allergen immunotherapy without specialist guidance. Pregnancy and lactation: use only if clearly needed after risk‑benefit discussion with a physician. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Itulazax may interact with certain medications; careful assessment is required.

Major Interactions (Avoid): - Concurrent use of beta‑blockers: may mask anaphylaxis symptoms. - ACE inhibitors: increase risk of angioedema. - Other sublingual immunotherapy products: may amplify immune response.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce local reaction, timing may need adjustment. - Systemic corticosteroids: may suppress the intended immunologic response. - Immunosuppressive agents: may diminish efficacy of the desensitization process.